關(guān)鍵詞

臨床研究 系統(tǒng)性紅斑狼瘡 PD-1 抗體反應(yīng) 瑞武麗珠單抗 MOGAD 克立硼羅 布西珠單抗 RSV疫苗

?

#今日行業(yè)熱點(diǎn)#

①New England Journal of Medicine：Selective Inhibition of NaV1.8 with VX-548 for Acute Pain

臨床研究：VX-548選擇性抑制NaV1.8對(duì)急性疼痛的影響

DOI: 10.1056/NEJMoa2209870

②Annals of the Rheumatic Diseases：Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets

綜述：系統(tǒng)性紅斑狼瘡（SLE）發(fā)病風(fēng)險(xiǎn)、疾病機(jī)制和治療靶點(diǎn)的研究

DOI: 10.1136/ard-2022-223741

③Gut：Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients

程序性細(xì)胞死亡蛋白1 (PD-1)異構(gòu)體Δ42PD-1在HCC進(jìn)展和納武利尤單抗免疫檢查點(diǎn)阻斷(ICB)耐藥中的作用

DOI: 10.1136/gutjnl-2022-327133

④Antiviral Research：Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice

Mpox病毒mRNA-脂質(zhì)納米顆粒候選疫苗(mRNA-LNP)在小鼠中引起抗體反應(yīng)并驅(qū)動(dòng)對(duì)痘苗病毒攻擊的保護(hù)

DOI: 10.1016/j.antiviral.2023.105668

⑤Journal of Neurology：Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

臨床試驗(yàn)：瑞武麗珠單抗（Ravulizumab）用于抗乙酰膽堿受體抗體陽(yáng)性全身型重癥肌無(wú)力成人患者的長(zhǎng)期療效和安全性:CHAMPION MG開放標(biāo)簽3期擴(kuò)展研究的結(jié)果

DOI: 10.1007/s00415-023-11699-x

⑥Journal of Neurology：Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges

綜述：髓鞘少突膠質(zhì)細(xì)胞糖蛋白抗體相關(guān)疾病( MOGAD)臨床認(rèn)識(shí)和當(dāng)前挑戰(zhàn)

DOI: 10.1007/s00415-023-11737-8

⑦小分子非激素磷酸二酯酶4（PDE-4）抑制劑克立硼羅獲國(guó)家藥監(jiān)局批準(zhǔn)新適應(yīng)癥，推測(cè)用于3個(gè)月及以上兒童和成人特應(yīng)性皮炎

⑧小分子BRAF抑制劑ABM-1310獲FDA授予孤兒藥資格，用于BRAF V600突變的腦膠質(zhì)母細(xì)胞瘤 (GBM)

⑨VEGF單抗布西珠單抗（brolucizumab）上市申請(qǐng)獲CDE受理，擬用于糖尿病性黃斑水腫（DME）

⑩GSK在美對(duì)輝瑞提起訴訟，稱輝瑞的RSV疫苗Abrysvo侵犯了GSK疫苗Arexvy的四項(xiàng)專利

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！